Since entering the orthobiologics business late 2021, the company has had a natural gravity towards the Eastern US. However, during 2025 OssDsign has increasingly been building its commercial footprint in the Western US, culminating in this agreement it states.

“This new contract win is a direct result of the strong clinical peer-reviewed PROPEL data showing 88.4% fusion rate in a challenging patient cohort as well as the preclinical Ovine results published earlier this year. It is clear that OssDsign Catalyst’s differentiation and strong clinical outcomes is giving us critical leverage,” says Morten Henneveld, CEO of OssDsign.